In this context, cetuximab (CTX) (i.e. monoclonal antibody targeting EGFR) was approved in 2006 by the FDA for HNSCC treatment in combination with radiotherapy6. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.